7th January 2016 - New research
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/26725544
http://www.viartis.net/parkinsons.disease/news/160107.pdf mail@viartis.net
©2016 Viartis
Opicapone is a COMT inhibitor presently being assessed as a possible replacement for the
COMT inhibitor Entacapone in its use in Parkinsons' Disease. COMT inhibitors are added to
the use of L-dopa to enhance its effect because COMT inhibitors help to prevent the
breakdown of L-dopa. Entacapone is presently the most widely used COMT inhibitor for use
in Parkinson's Disease. For more information go to : http://www.rxlist.com/comtan-drug.htm
A comparison was made between the use of a placebo, oral
treatment with opicapone (5 mg, 25 mg, or 50 mg once daily), or
entacapone (200 mg with every L-dopa intake). The reduction in off
times were 56 minutes for a placebo, 96 minutes for entacapone, 91
minutes for 5mg opicapone, 86 minutes for 25mg opicapone, and,
best of all, 116 minutes for 50mg opicapone. Adverse effects were
reported in 50% of people taking a placebo, 57% taking entacapone,
52% taking 5mg opicapone, 55% taking 25mg opicapone, and 54%
taking 50mg opicapone.
The most common adverse effects were dyskinesia, insomnia and constipation. There was
little difference in this respect between entacapone and certain dosages of opicapone.
The advantages of higher dosages of opicapone over entacapone means that opicapone has
the potential to replace entacapone.
Reference : [3] Lancet Neurol [2015] Dec 22 [Epub ahead of print] (J.J.Ferreira, A. Lees,
J.F.Rocha, W.Poewe, O.Rascol, P.Soares-da-Silva)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/26725544
http://www.viartis.net/parkinsons.disease/news/160107.pdf mail@viartis.net
©2016 Viartis
No comments:
Post a Comment